Sanofi Invests €1.3 Billion in New Insulin Manufacturing Plant in Frankfurt

Investment Amount: Sanofi is investing €1.3 billion into the new facility.
Location: The plant will be located at Sanofi's BioCampus in Frankfurt, Germany.
Facility Size: The facility will cover an area of 36,000 square meters.
Technology: The plant will utilize "digital and network solutions" for insulin production.
Purpose: The investment aims to enhance long-term insulin supply and strengthen Sanofi's European supply chain.
Beneficiaries: The new facility will primarily produce insulin for diabetes patients.
Source: The information is confirmed by multiple sources, including ENDPOINTS and NewsNow.